SAN DIEGO, Oct. 8 -- Pediatric infectious disease specialists have no consensus about the optimal approach to treatment of methicillin-resistant Staphylococcus aureus infections in children, a nationwide survey indicated.
No universal agreement exists for the choice of first-line therapy or the duration of therapy, Buddy Creech, M.D., of Vanderbilt University in Nashville, said at the Infectious Diseases Society of America meeting here.
A little more than half of the survey respondents favored clindamycin as first-line therapy, followed by trimethoprim/sulfamethoxazole. About a third of the physicians said they treat for 10 days, but two thirds cited durations ranging from fewer than seven days to more than 14.
"This is a huge problem," said Dr. Creech. "Three fourths of the abscesses treated in our emergency department involve MRSA. It's been that way for at least half a decade."